• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Canopy Growth Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    2/7/25 7:06:45 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $CGC alert in real time by email
    8-K
    false000173792700-000000000017379272025-02-072025-02-07

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    FORM 8-K

    CURRENT REPORT

    PURSUANT TO SECTION 13 OR 15(d)

    OF THE SECURITIES EXCHANGE ACT OF 1934

    Date of Report (Date of earliest event reported): February 7, 2025

    Canopy Growth Corporation

    (Exact name of registrant as specified in its charter)

     

    Canada

    001-38496

    N/A

    (State or other jurisdiction

    of incorporation)

    (Commission

    File Number)

    (IRS Employer

    Identification No.)

     

     

     

    1 Hershey Drive
    Smiths Falls, Ontario

    K7A 0A8

    (Address of principal executive offices)

    (Zip Code)

     

    (855) 558-9333

    (Registrant’s telephone number, including area code)

    Not Applicable

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

    Title of each class

     

    Trading

    Symbol(s)

     

    Name of each exchange on which registered

    Common Shares, no par value

     

    CGC

     

    NASDAQ Global Select Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     


     

    Item 2.02 Results of Operations and Financial Condition.

     

    On February 7, 2025, Canopy Growth Corporation issued a press release announcing its financial results for its fiscal third quarter ended December 31, 2024. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

     

    The information set forth in Item 2.02 of this Current Report on Form 8-K (“Current Report”), including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of such section. The information set forth in Item 2.02 of this Current Report, including Exhibit 99.1 attached hereto, shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any incorporation by reference language in any such filing.

     

    Item 9.01 Financial Statements and Exhibits.

    (d) Exhibits.

     

    Exhibit No.

    Description

     99.1*

    Press release dated February 7, 2025

     

     

     

     104

    Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

    * Filed herewith.

     

     


     

    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

     

     

     

     

    CANOPY GROWTH CORPORATION

     

     

     

     

    Date: February 7, 2025

     

    By:

    /s/ Judy Hong

     

     

     

    Judy Hong

     

     

     

    Chief Financial Officer

     

     


    Get the next $CGC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CGC

    DatePrice TargetRatingAnalyst
    4/4/2023Underperform → Mkt Perform
    Bernstein
    11/2/2022$1.50Underperform
    Bernstein
    10/26/2022Sell → Hold
    Canaccord Genuity
    6/8/2022Market Perform → Underperform
    BMO Capital Markets
    3/22/2022Equal Weight → Underweight
    Barclays
    3/1/2022$14.00 → $9.00Equal-Weight
    Barclays
    2/18/2022$9.60 → $11.00Neutral
    Cantor Fitzgerald
    12/22/2021Neutral → Underperform
    BofA Securities
    More analyst ratings

    $CGC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Canopy Growth Corporation (Amendment)

      SC 13D/A - Canopy Growth Corp (0001737927) (Subject)

      4/19/24 5:00:49 PM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13D/A filed by Canopy Growth Corporation (Amendment)

      SC 13D/A - Canopy Growth Corp (0001737927) (Subject)

      11/3/23 4:30:53 PM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13D/A filed by Canopy Growth Corporation (Amendment)

      SC 13D/A - Canopy Growth Corp (0001737927) (Subject)

      7/20/23 4:35:52 PM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care

    $CGC
    SEC Filings

    See more
    • Canopy Growth Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Canopy Growth Corp (0001737927) (Filer)

      4/1/25 7:54:00 AM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • Canopy Growth Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Canopy Growth Corp (0001737927) (Filer)

      2/28/25 5:19:22 PM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 424B5 filed by Canopy Growth Corporation

      424B5 - Canopy Growth Corp (0001737927) (Filer)

      2/28/25 5:17:50 PM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care

    $CGC
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $CGC
    Leadership Updates

    Live Leadership Updates

    See more

    $CGC
    Financials

    Live finance-specific insights

    See more

    $CGC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $CGC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Canopy Growth Drives Innovation in High-Demand Segments With Latest Product Launches

      Offerings reflect a focused format strategy in Canada's adult-use market Vapes, high-THC flower, pre-roll joints, and edibles introduced across core brands Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC), a world-leading cannabis company dedicated to unleashing the power of cannabis to improve lives, has launched a series of product innovations targeting Canada's fastest-growing adult-use categories.1 The lineup reflects a focused strategy built around four high-demand formats: vapes, high-THC flower, pre-rolls (including infused), and edibles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20

      5/6/25 7:30:00 AM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • Canopy Growth and Spectrum Therapeutics Announce Spectrum Reserve, A New Premium Medical Cannabis Brand

      New Brand Features Premium Genetics, Selected for Potency, Terpenes, and Consistency Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC), a world-leading cannabis company dedicated to unleashing the power of cannabis to improve lives, has launched Spectrum Reserve, a new premium medical cannabis brand in Canada. Designed to meet the evolving needs of medical cannabis patients, Spectrum Reserve represents the peak of cannabis cultivation – featuring flower selected for size, potency, and terpene levels through rigorous in-house standards during cultivation and post-harvest. Under this new program, Spectrum Reserve is expected to introduce new strains on a r

      4/2/25 7:30:00 AM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • Canopy Growth Strengthens Balance Sheet with Optional Early Prepayment to Reduce Term Loan by US$100 Million

      Early Prepayment Reduces Annual Interest Expense by US$13 Million, Extends Maturity of Term Loan to September 2027 This news release constitutes a "designated news release" for the purposes of Canopy Growth's prospectus supplement dated June 6, 2024 to its short form base shelf prospectus dated February 28, 2025 Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC), a world-leading cannabis company dedicated to unleashing the power of cannabis to improve lives, announced today that it has made an optional early prepayment under its senior secured term loan (the "Term Loan") in an aggregate principal amount equal to US$100 million at a discounted price of US

      4/1/25 7:30:00 AM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • Canopy USA Announces Appointment of Mr. M. Brooks Jorgensen as President

      A cannabis and beverage alcohol industry executive with more than 25 years of experience, Mr. Jorgensen will lead the unified Canopy USA organization forward with a focus on driving profitable growth across the U.S. With the completed acquisitions of Acreage, Wana, and Jetty, Canopy USA now enters a new chapter of growth across key segments including flower, edibles, vapes, extracts, and through an established retail presence in high potential markets across the Midwest and Northeast BOULDER, Colo., January 6, 2025 /PRNewswire/ - Canopy USA, LLC ("Canopy USA"), a brand-driven organization strategically positioned across the fastest growing states and highest potential segments of the U.S. c

      1/6/25 7:30:00 AM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • Canopy Growth Announces Results of Annual General Meeting

      SMITHS FALLS, ON, Sept. 25, 2024 /PRNewswire/ - Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC) is pleased to announce today the voting results from its annual general meeting of shareholders held on September 24, 2024 (the "Meeting"). All of the matters put forward before the Company's shareholders for consideration and approval, as set out in the Company's definitive proxy statement dated August 1, 2024 (the "Proxy Statement"), were approved by the requisite number of votes cast at the Meeting, as further detailed below. Each of the direc

      9/25/24 7:30:00 AM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • Canopy Growth Announces Extension of Proxy Voting Deadline for Upcoming Annual General Meeting

      Shareholders now have until September 24, 2024 at 9:00 a.m. (Eastern Time) to submit votes to help ensure a quorum is achieved Your Vote is Important! If you need assistance with voting your shares please contact Laurel Hill Advisory Group at 1-877-452-7184 or by e-mail at [email protected] SMITHS FALLS, ON, Sept. 20, 2024 /PRNewswire/ - Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC) announced today that it has extended the deadline for the submission of proxies related to its upcoming annual general meeting of shareholders (the "Meeting") to September 24, 2024 at 9:00 a.m. (Eastern time). The Meeting will be held later the same day, at 1:00 p.m.

      9/20/24 4:45:00 PM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • The Week in Canadian Press Releases: 10 Stories You Need to See

      A roundup of the most newsworthy press releases from Cision Distribution this week TORONTO, Feb. 14, 2025 /CNW/ - With thousands of press releases published each week, it can be difficult to keep up with everything on Cision. To help journalists and consumers stay on top of the week's most newsworthy and popular releases, here's a recap of some major stories from the week that shouldn't be missed. The list below includes the headline (with a link to the full text) and an excerpt from each story. Click on the press release headlines to access accompanying multimedia assets that

      2/14/25 6:18:00 AM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • Canopy Growth Reports Third Quarter Fiscal Year 2025 Financial Results

      Strong holiday sales drove Storz & Bickel net revenue growth of 19% year-over-year   Record quarter for Canada medical cannabis with net revenue increasing 16%; international markets cannabis net revenue grew 14% year-over-year    Successfully launched Claybourne infused pre-rolls across Canada, Claybourne rose to #3 market share in the infused pre-roll category in British Columbia and Ontario after 6 weeks in market1 SMITHS FALLS, ON, Feb. 7, 2025 /PRNewswire/ - Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC) today announces its financial results for the third fiscal quarter ended December 31, 2024 ("Q3 FY2025"). All financial information in this press

      2/7/25 7:00:00 AM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • Canopy Growth to Report Third Quarter Fiscal 2025 Financial Results on February 7, 2025

      SMITHS FALLS, ON, Jan. 24, 2025 /PRNewswire/ - Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC) will release its financial results for the third quarter fiscal year 2025 ended December 31, 2024 before financial markets open on February 7, 2025. Following the release of its third quarter fiscal year 2025 financial results, Canopy Growth will host an audio webcast with Luc Mongeau, CEO and Judy Hong, CFO on February 7 at 10 AM Eastern Time (ET). Webcast Information A live audio webcast will be available at: https://app.webinar.net/yY1K7LrWq9O

      1/24/25 7:30:00 AM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Yanofsky Theresa sold $1,844 worth of shares (2,004 units at $0.92), decreasing direct ownership by 9% to 20,199 units (SEC Form 4)

      4 - Canopy Growth Corp (0001737927) (Issuer)

      4/2/25 4:17:13 PM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Lazzarato David Angelo sold $2,764 worth of shares (3,004 units at $0.92), decreasing direct ownership by 12% to 22,886 units (SEC Form 4)

      4 - Canopy Growth Corp (0001737927) (Issuer)

      4/2/25 4:16:37 PM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Kruh Willy sold $1,851 worth of shares (2,012 units at $0.92), decreasing direct ownership by 18% to 9,272 units (SEC Form 4)

      4 - Canopy Growth Corp (0001737927) (Issuer)

      4/2/25 4:15:15 PM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • Canopy Growth upgraded by Bernstein

      Bernstein upgraded Canopy Growth from Underperform to Mkt Perform

      4/4/23 9:09:41 AM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • Bernstein initiated coverage on Canopy Growth with a new price target

      Bernstein initiated coverage of Canopy Growth with a rating of Underperform and set a new price target of $1.50

      11/2/22 6:11:10 AM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • Canopy Growth upgraded by Canaccord Genuity

      Canaccord Genuity upgraded Canopy Growth from Sell to Hold

      10/26/22 7:36:52 AM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care